EI
GBIO

Ellevest Inc’s Generation Bio GBIO Stock Holding History

Ellevest Inc’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80
Closed -$4K – 1886
2022
Q3 		$4K Buy
+80
New +$5K ﹤0.01% 1219

Other funds holding GBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Ellevest Inc's GBIO Position: Q4 2022 in Review

Ellevest Inc sold out of Generation Bio (GBIO) in Q4 2022, closing a stake of 80 shares — an estimated $4K sold.

Ellevest Inc first reported a position in GBIO in Q3 2022 and held it in 1 quarter. The position peaked at $4K in Q3 2022. 95 funds tracked by Wall St. Rank hold GBIO as of Q4 2022.

  • Ellevest Inc reported no remaining Generation Bio position as of Q4 2022 after selling out during the quarter.
  • Ellevest Inc sold 80 Generation Bio shares in Q4 2022, an estimated $4K.
  • Ellevest Inc first reported a position in Generation Bio in Q3 2022 and held it in 1 quarter.
  • Ellevest Inc's Generation Bio position peaked at $4K in Q3 2022.
  • 95 funds tracked by Wall St. Rank held Generation Bio as of Q4 2022.

Based on Ellevest Inc's 13F filing for Q4 2022, filed 3 Feb 2023.